
|
 |
CONTENTS
Adaptive and dynamic methods of treatment assignment
Antibacterial agent trials
Audit and quality control
Bayesian methods
Benefit/risk assessment
Blinding or masking
Clinical significance versus statistical significance
Clinical trials, overview
Cluster randomization
Cochrane collaboration
Community intervention trials
Compliance assessment
CONSORT Controlled clinical trials (J)
Cooperative cancer trials
Cooperative heart disease trials
Cooperative studies program, US Department of Veterans Affairs
Cost-effectiveness
Covariate imbalance, adjustment for
Crossover designs
Data and safety monitoring
Data and safety monitoring boards
Data management and coordination
Drug approval and regulation
Drug interactions
Eligibility and exclusion criteria
Equivalence trials
Ethics
European Federation of Statisticians in the Pharmaceutical Industry (EPSPI)
European Organization for Research and Treatment of Cancer (EORTC)
Factorial designs
Fraud
Group-randomization designs
Guidelines
Historical controls, bias from
History, early cancer and heart disease trials
History, overview
Intention to treat analysis
International Studies of Infarct Survival (ISIS)
Medical ethics and statistics (with new material)
Medical Research Council (MRC) Streptomycin Trial
Meta-analysis
Missing data
Multicenter trials
Multiple endpoints
Multiplicity
Noncompliance, adjustment for
Nonrandomized trials
NSABP and advances in the treatment of breast cancer
Number needed to treat (NNT)
Outcome measures
Pharmaceutical industry, statistics in
Phase I trials
Phase II trials
Physicians' health study
Postmarketing surveillance of new drugs and assessment of risk
Preclinical treatment evaluation
Prevention trials
Protocols
QUOROM
Randomization
Randomized treatment assignment
Salk vaccine
Sample size determination
Screening trials
Sequential methods
Society for Clinical Trials
Software
Statistical review for medical journals
Statistical review for medical journals, guidelines for authors
Statistician in the pharmaceutical industry (PSI)
Surrogate endpoints
Textbooks
Time-varying treatment effect
Treatment-covariate interaction
University Group Diabetes Program (UGDP)
Vaccine studies
Main Page for this Work
Table of Contents
About the Editors
Sample Articles
|